© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to June
low-dose CNS-penetrant BACE inhibitor
90% red. of CSF A_ in Ph. II at 9.2 mg / discont.
from opt. vs. CatD and dose red. of prior leads
Journal of Medicinal Chemistry
Eli Lilly, Indianapolis, US
6. The Lilly beta-site APP cleaving enzyme (BACE) inhibitor LY3202626 is an oral, low-dose, CNS-penetrant molecule which entered a Phase II of clinical trial against AlzheimerÕs disease in 2016.…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.